Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response

Harm HogenEsch, Anisa Dunham, Bethany Hansen, Kathleen Anderson, Jean Francois Maisonneuve, Stanley L. Hem

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing adjuvants for intramuscular injection.Methods: Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.Results: Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.Conclusions: Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17 response. These experiments underscore the importance of formulation studies with aluminium containing adjuvants for the development of stable and effective vaccines.

Original languageEnglish (US)
Article number5
JournalJournal of Immune Based Therapies and Vaccines
Volume9
DOIs
StatePublished - Jul 29 2011
Externally publishedYes

Fingerprint

Interleukin-17
Streptococcus pneumoniae
Aluminum
Vaccines
Aluminum Hydroxide
Antibodies
Antigens
Antibody Formation
Polysaccharides
Pneumococcal Vaccines
Intramuscular Injections
Phosphates
Morbidity
Mortality

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. / HogenEsch, Harm; Dunham, Anisa; Hansen, Bethany; Anderson, Kathleen; Maisonneuve, Jean Francois; Hem, Stanley L.

In: Journal of Immune Based Therapies and Vaccines, Vol. 9, 5, 29.07.2011.

Research output: Contribution to journalArticle

HogenEsch, Harm ; Dunham, Anisa ; Hansen, Bethany ; Anderson, Kathleen ; Maisonneuve, Jean Francois ; Hem, Stanley L. / Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. In: Journal of Immune Based Therapies and Vaccines. 2011 ; Vol. 9.
@article{5f8b9381116c4546912c7be4fe8dfdc8,
title = "Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response",
abstract = "Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing adjuvants for intramuscular injection.Methods: Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.Results: Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.Conclusions: Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17 response. These experiments underscore the importance of formulation studies with aluminium containing adjuvants for the development of stable and effective vaccines.",
author = "Harm HogenEsch and Anisa Dunham and Bethany Hansen and Kathleen Anderson and Maisonneuve, {Jean Francois} and Hem, {Stanley L.}",
year = "2011",
month = "7",
day = "29",
doi = "10.1186/1476-8518-9-5",
language = "English (US)",
volume = "9",
journal = "Journal of Immune Based Therapies and Vaccines",
issn = "1476-8518",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response

AU - HogenEsch, Harm

AU - Dunham, Anisa

AU - Hansen, Bethany

AU - Anderson, Kathleen

AU - Maisonneuve, Jean Francois

AU - Hem, Stanley L.

PY - 2011/7/29

Y1 - 2011/7/29

N2 - Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing adjuvants for intramuscular injection.Methods: Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.Results: Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.Conclusions: Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17 response. These experiments underscore the importance of formulation studies with aluminium containing adjuvants for the development of stable and effective vaccines.

AB - Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing adjuvants for intramuscular injection.Methods: Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.Results: Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.Conclusions: Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17 response. These experiments underscore the importance of formulation studies with aluminium containing adjuvants for the development of stable and effective vaccines.

UR - http://www.scopus.com/inward/record.url?scp=79960888602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960888602&partnerID=8YFLogxK

U2 - 10.1186/1476-8518-9-5

DO - 10.1186/1476-8518-9-5

M3 - Article

C2 - 21801401

AN - SCOPUS:79960888602

VL - 9

JO - Journal of Immune Based Therapies and Vaccines

JF - Journal of Immune Based Therapies and Vaccines

SN - 1476-8518

M1 - 5

ER -